ESC 365 - Direct oral anticoagulant rivaroxaban in very old and frail patients: A one-year prospective follow-up of a large-scale cohort (SAFIR-AC)

ESC Premium Access

Direct oral anticoagulant rivaroxaban in very old and frail patients: A one-year prospective follow-up of a large-scale cohort (SAFIR-AC)

Session: Atrial fibrillation: from drugs to ablation

Topic: Antiarrhythmic Drug Treatment

Speaker: Professor O. Hanon (Paris, FR)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Olivier Hanon

Hospital Broca of Paris, Paris (France)

2 presentations

0 follower

3 more presentations in this session

Blood pressure and white matter lesions in patients with atrial fibrillation

Speaker: Professor D. Conen (Hamilton, CA)

Impact of AF type on the outcome of atrial fibrillation ablation: insights from the CABANA trial

Speaker: Assistant Professor K. Monahan (Rochester, US)

Are the results of the CASTLE-AF trial reproducible in the real life? Clinical outcomes after catheter ablation for atrial fibrillation with heart failure in a nationwide cohort study

Speaker: Professor L. Fauchier (Tours, FR)

Access the full session

Atrial fibrillation: from drugs to ablation

Speakers: Professor O. Hanon, Professor D. Conen, Assistant Professor K. Monahan, Professor L. Fauchier

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources